

<Press Release>

Jun 7, 2022

Chordia Therapeutics Concludes Basic Agreement on Collaboration  
with Shionogi Pharma Co., Ltd.

Kanagawa, Japan, May 19, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it signed a basic agreement on collaboration with Shionogi Pharma, Co., Ltd. (“Shionogi Pharma”)

Based on the basic collaboration agreement, Chordia will proceed with specific discussions with Shionogi Pharma regarding the production of small-molecule compounds. Shionogi Pharma has extensive know-how including analytical and API formulation manufacturing capabilities in the production of small-molecule compounds from drug development to the commercial stage. Chordia expects that collaborating with Shionogi Pharma on the manufacturing of our oncology pipeline will promote the development of high-quality small-molecule anti-cancer drugs and contribute to delivering new treatment options to patients.

About Shionogi Pharma

Shionogi Pharma started its business April 1, 2019 with the mission “to become contract development and manufacturing organization trusted by our customers.” Shionogi Pharma can provide “Full-range Services” for development of APIs and drug products as well as their commercial manufacturing. Shionogi Pharma can also provide services for developing analytical methods and designing pharmaceutical facilities based on its pharmaceutical engineering technologies.

Established: October 2018

Business Description: Manufacture, sales, analysis and testing, and pharmaceutical engineering of ethical drugs, investigational drugs, veterinary drugs, etc.

Location: 5-1, Mishima 2-chome, Settsu, Osaka 566-0022, Japan

Representative: Ryuichi Kume, President & CEO

Website: <https://www.shionogi-ph.co.jp/en/>

About Chordia Therapeutics

Chordia was established in November 2017 at Shonan Health Innovation Park (“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in the research and development of novel therapies for cancers, with the goal of researching and developing first-in-class anti-cancer drugs and creating innovative new drugs.

The CLK inhibitor CTX-712, which is currently under development as the lead program, is currently undergoing Phase I clinical trials in Japan for patients with advanced, relapsed or refractory malignancies. CTX-712 targets vulnerabilities

## Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan  
info@chorditherapeutics.com



---

resulting from RNA deregulation, which has been identified as a new hallmark of cancer, and is expected to be an effective therapeutic agent.

In addition to its leading program for CTX-712, Chordia is engaged in the research of several developments in our pipeline, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2 chome, Fujisawa, Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact Kentaro Kume, IR: [info@chorditherapeutics.com](mailto:info@chorditherapeutics.com)